| [1] |
Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3[J]. Nat Rev Cancer,2009,9(7):463-475.
|
| [2] |
Telesco SE, Radhakrishnan R. Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain:a molecular dynamics study [J]. Biophys J,2009,96(6):2321-2334.
|
| [3] |
Helikar T, Kochi N, Kowal B, et al. A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells [J]. PLoS One,2013,8(4):e61757.
|
| [4] |
Fan X, Furnari FB, Cavenee WK, et al. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells [J]. Int J Oncol,2001,18 (5):1023-1026.
|
| [5] |
李玉梅,姚纪元,吴静,等.PCR-SSCP 技术的研究及应用进展[J].生物技术通报,2007,32(6):71-73.
|
| [6] |
Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) [J]. Br J Cancer, 2007, 97 (6):778-784.
|
| [7] |
Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number[J].Anal Chem,2011,83(22):8604-8610.
|
| [8] |
Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer [J]. Cancer Discov,2013,3(2):224-237.
|
| [9] |
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature,2012,490(74):61-70
|
| [10] |
Endo Y, Dong Y, Kondo N, et al. HER2 mutation status in Japanese HER2-positive breast cancer patients [J]. Breast Cancer, 2015, 12:1-7.
|
| [11] |
Fang Y, Jiang Y, Wang X, et al. Somatic mutations of the HER2 in metastatic breast cancer[J]. Tumor Biol,2014,35(12):11 851-11 854.
|
| [12] |
Park YH, Shin HT, Jung HH, et al. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer [J]. Oncotarget, 2015,6(31):32 027-32 038.
|
| [13] |
Ross JS, Wang K, Sheehan CE, et al. Relapsed classic E-cadherin(CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations[J]. Clin Cancer Res, 2013,19(10):2668-2676.
|
| [14] |
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors [J]. Nat Rev Cancer,2005,5(5):341-354.
|
| [15] |
Arcila ME, Chaft JE, Nafa K, et al. Prevalence,clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas[J]. Clin Cancer Res,2012,18(18):4910-4918.
|
| [16] |
Lee JW, Soung YH, Seo SH, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas[J]. Clin Cancer Res,2006,12(1):57-61.
|
| [17] |
Ellis MJ. Mutational analysis of breast cancer: guiding personalized treatments [J]. Breast,2013,22 Suppl 2:S19-21.
|
| [18] |
Greulich H, Kaplan B, Mertins P, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2[J]. Proc Natl Acad Sci USA,2012,109(36):14 476-14 481.
|
| [19] |
Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers [J]. Nature, 2010,466(7308):869-873.
|
| [20] |
Xie D, Shu XO, Deng Z, et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk [J]. J Natl Cancer Inst,2000,92(5):412-417.
|
| [21] |
Lu S, Wang Z, Liu H, et al. HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies[J]. Breast Cancer Res Treat,2010,124(3):771-778.
|
| [22] |
Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review[J]. J Clin Oncol,2010,28(1):92-98.
|
| [23] |
Tortora G. Mechanisms of resistance to HER2 target therapy [J]. J Natl Cancer Inst Monogr,2011,2011(43):95-98.
|
| [24] |
Wong H, Leung R, Kwong A, et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2 + metastatic breast cancer[J]. Oncologist, 2011,16(11):1535-1546.
|
| [25] |
Prempree T, Wongpaksa C. Mutations of HER2 gene in HER2-positive metastatic breast [ EB/OL ]. [ 2016-01-20 ]. http:/ /meeting.ascopubs. org/cgi/content/abstract/24/18 _ suppl/13118? sid =c646c5cd-3059-4253-a3fd-17ca286481d9.
|
| [26] |
National Comprehensive Cancer Network. NCCN guidelines: breast cancer 2015 v3[EB/OL]. [2016-01-20]. http:/ /www. nccn. org/professionals/physician_gls/f_guidelines.asp.
|
| [27] |
Meng X, Li Y, Tang H, et al. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer[J]. Amino Acids,2016,48(2):487-497.
|
| [28] |
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer [J]. N Engl J Med,2015,372(8):724-734.
|
| [29] |
Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumabbased adjuvant therapy in patients with HER2-positive breast cancer(ExteNET): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial[J]. Lancet Oncol,2016,17(3):367-377.
|
| [30] |
Ma CX, Bose R, Gao F, et al. Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC)[EB/OL]. [2016-01-20]. http:/ /meeting. ascopubs. org/cgi/content/abstract/34/15_suppl/516? sid=6a457b12-32f9-4342-ad91-c67f58dc02bd.
|